Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells 2,747 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMSGet Free Report) insider Irene Becklund sold 2,747 shares of the stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $12.08, for a total transaction of $33,183.76. Following the completion of the sale, the insider now directly owns 5,494 shares of the company’s stock, valued at $66,367.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Irene Becklund also recently made the following trade(s):

  • On Tuesday, December 19th, Irene Becklund sold 10,597 shares of Hims & Hers Health stock. The shares were sold at an average price of $8.73, for a total transaction of $92,511.81.

Hims & Hers Health Price Performance

Shares of NYSE HIMS traded down $0.09 during midday trading on Wednesday, hitting $13.34. The company’s stock had a trading volume of 12,964,635 shares, compared to its average volume of 3,955,094. The business’s fifty day simple moving average is $9.13 and its two-hundred day simple moving average is $7.75. Hims & Hers Health, Inc. has a 1 year low of $5.65 and a 1 year high of $13.91. The firm has a market capitalization of $2.83 billion, a price-to-earnings ratio of -121.36 and a beta of 0.77.

Hims & Hers Health (NYSE:HIMSGet Free Report) last issued its quarterly earnings results on Monday, February 26th. The company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.03. Hims & Hers Health had a negative net margin of 2.70% and a negative return on equity of 7.34%. The company had revenue of $246.60 million during the quarter, compared to the consensus estimate of $245.84 million. During the same quarter in the previous year, the firm earned ($0.05) earnings per share. The firm’s quarterly revenue was up 47.4% on a year-over-year basis. Analysts anticipate that Hims & Hers Health, Inc. will post -0.08 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently commented on HIMS. SVB Leerink began coverage on shares of Hims & Hers Health in a report on Monday. They issued a “market perform” rating and a $10.00 price target for the company. Leerink Partnrs restated a “market perform” rating on shares of Hims & Hers Health in a report on Monday. Tigress Financial boosted their price target on shares of Hims & Hers Health from $14.00 to $15.00 and gave the company a “buy” rating in a report on Friday, January 5th. Truist Financial boosted their price objective on shares of Hims & Hers Health from $10.00 to $13.00 and gave the stock a “hold” rating in a research note on Tuesday. Finally, Imperial Capital upgraded shares of Hims & Hers Health from an “in-line” rating to an “outperform” rating and set a $16.00 price objective for the company in a research note on Wednesday. Five analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $13.08.

Get Our Latest Research Report on HIMS

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. CM Wealth Advisors LLC acquired a new stake in Hims & Hers Health during the second quarter worth approximately $25,000. Point72 Middle East FZE acquired a new stake in Hims & Hers Health during the fourth quarter worth approximately $29,000. Captrust Financial Advisors raised its holdings in Hims & Hers Health by 1,827.4% during the first quarter. Captrust Financial Advisors now owns 6,765 shares of the company’s stock worth $36,000 after purchasing an additional 6,414 shares in the last quarter. Harbour Investments Inc. raised its holdings in Hims & Hers Health by 427.9% during the third quarter. Harbour Investments Inc. now owns 6,995 shares of the company’s stock worth $44,000 after purchasing an additional 5,670 shares in the last quarter. Finally, Belpointe Asset Management LLC acquired a new stake in Hims & Hers Health during the first quarter worth approximately $46,000. Hedge funds and other institutional investors own 61.45% of the company’s stock.

Hims & Hers Health Company Profile

(Get Free Report)

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care.

Featured Articles

Insider Buying and Selling by Quarter for Hims & Hers Health (NYSE:HIMS)

Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.